441 related articles for article (PubMed ID: 32571632)
1. Involvement of Disabled-2 on skin fibrosis in systemic sclerosis.
Mei X; Zhao H; Huang Y; Tang Y; Shi X; Pu W; Jiang S; Ma Y; Zhang Y; Bai L; Tu W; Zhao Y; Jin L; Wu W; Wang J; Liu Q
J Dermatol Sci; 2020 Jul; 99(1):44-52. PubMed ID: 32571632
[TBL] [Abstract][Full Text] [Related]
2. CXCL17-mediated downregulation of type I collagen via MMP1 and miR-29 in skin fibroblasts possibly contributes to the fibrosis in systemic sclerosis.
Shimada S; Makino K; Jinnin M; Sawamura S; Kawano Y; Ide M; Kajihara I; Makino T; Fukushima S; Ihn H
J Dermatol Sci; 2020 Dec; 100(3):183-191. PubMed ID: 33055012
[TBL] [Abstract][Full Text] [Related]
3. Increased expression of GAB1 promotes inflammation and fibrosis in systemic sclerosis.
Shi X; Liu Q; Zhao H; Lu J; Huang Y; Ma Y; Xia J; Liu M; Tu W; Jin L; Wang J; Zhao Y; Wu W
Exp Dermatol; 2019 Nov; 28(11):1313-1320. PubMed ID: 31505074
[TBL] [Abstract][Full Text] [Related]
4. Salvianolic acid B attenuates experimental skin fibrosis of systemic sclerosis.
Liu Q; Lu J; Lin J; Tang Y; Pu W; Shi X; Jiang S; Liu J; Ma Y; Li Y; Xu J; Jin L; Wang J; Wu W
Biomed Pharmacother; 2019 Feb; 110():546-553. PubMed ID: 30530290
[TBL] [Abstract][Full Text] [Related]
5. Sirt1 ameliorates systemic sclerosis by targeting the mTOR pathway.
Zhu X; Chu H; Jiang S; Liu Q; Liu L; Xue Y; Zheng S; Wan W; Qiu J; Wang J; Zou H
J Dermatol Sci; 2017 Aug; 87(2):149-158. PubMed ID: 28532580
[TBL] [Abstract][Full Text] [Related]
6. GRB2 serves as a viable target against skin fibrosis in systemic sclerosis by regulating endothelial cell apoptosis.
Huang Y; Zhao H; Shi X; Liu J; Lin JM; Ma Q; Jiang S; Pu W; Ma Y; Liu J; Wu W; Wang J; Liu Q
J Dermatol Sci; 2023 Sep; 111(3):109-119. PubMed ID: 37661474
[TBL] [Abstract][Full Text] [Related]
7. Interferon regulatory factor 7 (IRF7) represents a link between inflammation and fibrosis in the pathogenesis of systemic sclerosis.
Wu M; Skaug B; Bi X; Mills T; Salazar G; Zhou X; Reveille J; Agarwal SK; Blackburn MR; Mayes MD; Assassi S
Ann Rheum Dis; 2019 Nov; 78(11):1583-1591. PubMed ID: 31439591
[TBL] [Abstract][Full Text] [Related]
8. Antifibrotic effects and mechanisms of mesenchymal stem cell-derived exosomes in a systemic sclerosis mouse model: Possible contribution of miR-196b-5p.
Baral H; Uchiyama A; Yokoyama Y; Sekiguchi A; Yamazaki S; Amalia SN; Inoue Y; Ogino S; Torii R; Hosoi M; Matsuzaki T; Motegi SI
J Dermatol Sci; 2021 Oct; 104(1):39-47. PubMed ID: 34479773
[TBL] [Abstract][Full Text] [Related]
9. Th17 cells and IL-17 promote the skin and lung inflammation and fibrosis process in a bleomycin-induced murine model of systemic sclerosis.
Lei L; Zhao C; Qin F; He ZY; Wang X; Zhong XN
Clin Exp Rheumatol; 2016; 34 Suppl 100(5):14-22. PubMed ID: 26750756
[TBL] [Abstract][Full Text] [Related]
10. Inhibitory effect of kaempferol on skin fibrosis in systemic sclerosis by the suppression of oxidative stress.
Sekiguchi A; Motegi SI; Fujiwara C; Yamazaki S; Inoue Y; Uchiyama A; Akai R; Iwawaki T; Ishikawa O
J Dermatol Sci; 2019 Oct; 96(1):8-17. PubMed ID: 31447184
[TBL] [Abstract][Full Text] [Related]
11. Tanshinone IIA ameliorates the development of dermal fibrosis in systemic sclerosis.
Jiang Y; Hu F; Li M; Li Q
Clin Exp Pharmacol Physiol; 2024 Feb; 51(2):e13834. PubMed ID: 38037494
[TBL] [Abstract][Full Text] [Related]
12. Pan PPAR agonist IVA337 is effective in prevention and treatment of experimental skin fibrosis.
Ruzehaji N; Frantz C; Ponsoye M; Avouac J; Pezet S; Guilbert T; Luccarini JM; Broqua P; Junien JL; Allanore Y
Ann Rheum Dis; 2016 Dec; 75(12):2175-2183. PubMed ID: 26961294
[TBL] [Abstract][Full Text] [Related]
13. Inhibitory Regulation of Skin Fibrosis in Systemic Sclerosis by Apelin/APJ Signaling.
Yokoyama Y; Sekiguchi A; Fujiwara C; Uchiyama A; Uehara A; Ogino S; Torii R; Ishikawa O; Motegi SI
Arthritis Rheumatol; 2018 Oct; 70(10):1661-1672. PubMed ID: 29676521
[TBL] [Abstract][Full Text] [Related]
14. Dersimelagon, a novel oral melanocortin 1 receptor agonist, demonstrates disease-modifying effects in preclinical models of systemic sclerosis.
Kondo M; Suzuki T; Kawano Y; Kojima S; Miyashiro M; Matsumoto A; Kania G; Błyszczuk P; Ross RL; Mulipa P; Del Galdo F; Zhang Y; Distler JHW
Arthritis Res Ther; 2022 Sep; 24(1):210. PubMed ID: 36050717
[TBL] [Abstract][Full Text] [Related]
15. The membrane-associated adaptor protein DOK5 is upregulated in systemic sclerosis and associated with IGFBP-5-induced fibrosis.
Yasuoka H; Yamaguchi Y; Feghali-Bostwick CA
PLoS One; 2014; 9(2):e87754. PubMed ID: 24551065
[TBL] [Abstract][Full Text] [Related]
16. Increased expression of latent TGF-β-binding protein 4 affects the fibrotic process in scleroderma by TGF-β/SMAD signaling.
Lu J; Liu Q; Wang L; Tu W; Chu H; Ding W; Jiang S; Ma Y; Shi X; Pu W; Zhou X; Jin L; Wang J; Wu W
Lab Invest; 2017 May; 97(5):591-601. PubMed ID: 28263294
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic Targeting of TAZ and YAP by Dimethyl Fumarate in Systemic Sclerosis Fibrosis.
Toyama T; Looney AP; Baker BM; Stawski L; Haines P; Simms R; Szymaniak AD; Varelas X; Trojanowska M
J Invest Dermatol; 2018 Jan; 138(1):78-88. PubMed ID: 28870693
[TBL] [Abstract][Full Text] [Related]
18. Dipeptidylpeptidase 4 as a Marker of Activated Fibroblasts and a Potential Target for the Treatment of Fibrosis in Systemic Sclerosis.
Soare A; Györfi HA; Matei AE; Dees C; Rauber S; Wohlfahrt T; Chen CW; Ludolph I; Horch RE; Bäuerle T; von Hörsten S; Mihai C; Distler O; Ramming A; Schett G; Distler JHW
Arthritis Rheumatol; 2020 Jan; 72(1):137-149. PubMed ID: 31350829
[TBL] [Abstract][Full Text] [Related]
19. Suppressive Regulation by MFG-E8 of Latent Transforming Growth Factor β-Induced Fibrosis via Binding to αv Integrin: Significance in the Pathogenesis of Fibrosis in Systemic Sclerosis.
Fujiwara C; Uehara A; Sekiguchi A; Uchiyama A; Yamazaki S; Ogino S; Yokoyama Y; Torii R; Hosoi M; Suto C; Tsunekawa K; Murakami M; Ishikawa O; Motegi SI
Arthritis Rheumatol; 2019 Feb; 71(2):302-314. PubMed ID: 30175895
[TBL] [Abstract][Full Text] [Related]
20. alpha-melanocyte-stimulating hormone suppresses bleomycin-induced collagen synthesis and reduces tissue fibrosis in a mouse model of scleroderma: melanocortin peptides as a novel treatment strategy for scleroderma?
Kokot A; Sindrilaru A; Schiller M; Sunderkötter C; Kerkhoff C; Eckes B; Scharffetter-Kochanek K; Luger TA; Böhm M
Arthritis Rheum; 2009 Feb; 60(2):592-603. PubMed ID: 19180474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
